Eli Lilly and Company (NYSE:LLY), a leading global pharmaceutical firm, finds itself at a pivotal juncture as it navigates a ...
A/S, a global healthcare giant specializing in diabetes care and obesity treatment, continues to dominate the GLP-1 drug market alongside competitor Eli Lilly (NYSE:LLY). With a market capitalization ...
Shares in Veru fell by nearly half following the news, despite positive results in preserving lean muscle mass.
Metsera has set its sights on a hefty $289 million IPO as the next-gen obesity biotech seeks to fund a phase 3 trial of its ...
The biotech has named Jamie Coleman its chief commercial officer, per a Monday announcement, putting her in charge of the ...
Lean mass constituted 30.8% of total body weight lost for adults who received a GLP-1 drug during a randomized controlled ...
FDA formally announced the end of the tirzepatide shortage in a Declaratory Order issued to Eli Lilly & Co. (“Lilly”). Lilly ...
Private Capital Advisors Inc. grew its holdings in shares of Eli Lilly and Company (NYSE:LLY – Free Report) by 0.1% during ...
Eli Lilly and Company ( NYSE:LLY – Get Free Report) last issued its quarterly earnings data on Wednesday, October 30th. The company reported $1.18 earnings per share (EPS) for the quarter, missing ...